奥翔药业(603229) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 306,636,220.57, representing a 1.90% increase compared to CNY 300,914,417.10 in the same period last year[3]. - Net profit attributable to shareholders was CNY 119,199,188.77, up 5.97% from CNY 112,480,834.45 year-on-year[3]. - The company reported a diluted earnings per share of CNY 0.14, unchanged from the previous year[3]. - Net profit for Q1 2025 was CNY 119,199,188.77, up 6.1% from CNY 112,480,834.45 in Q1 2024[16]. - The company reported a total comprehensive income of CNY 119,869,435.30 for Q1 2025, compared to CNY 112,485,569.05 in Q1 2024[16]. - Basic and diluted earnings per share remained stable at CNY 0.14 for both Q1 2025 and Q1 2024[16]. Cash Flow and Operating Activities - The net cash flow from operating activities decreased significantly by 92.42%, amounting to CNY 2,046,387.30, primarily due to increased payments for goods compared to the previous year[6]. - Cash flow from operating activities generated a net amount of CNY 2,046,387.30 in Q1 2025, down from CNY 26,983,529.17 in Q1 2024[19]. - The company experienced a net cash outflow from financing activities of CNY 15,083,389.51 in Q1 2025, an improvement from CNY 19,759,399.18 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,120,558,712.61, a 4.63% increase from CNY 2,982,390,050.39 at the end of the previous year[4]. - The company's current assets reached RMB 1,836,403,912.68, up from RMB 1,709,169,547.87, indicating an increase of about 7.43%[10]. - The accounts receivable increased significantly to RMB 326,512,713.44 from RMB 192,215,593.45, representing a growth of approximately 69.9%[10]. - The inventory decreased to RMB 384,355,661.51 from RMB 400,949,911.46, showing a decline of about 4.15%[10]. - The total liabilities of the company were RMB 748,785,133.12, compared to RMB 710,498,847.68, marking an increase of approximately 5.4%[12]. - The owner's equity totaled RMB 2,371,773,579.49, up from RMB 2,271,891,202.71, reflecting an increase of about 4.4%[12]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,806[7]. - The largest shareholder, Zheng Zhiguo, holds 50.64% of the shares, totaling 420,433,703 shares[7]. Other Financial Metrics - The weighted average return on equity was 5.11%, a slight decrease of 0.01 percentage points from 5.12% in the previous year[3]. - The company recognized non-recurring gains of CNY 2,408,407.73 from government subsidies related to its normal business operations[5]. - Research and development expenses rose to CNY 28,303,999.30 in Q1 2025, compared to CNY 23,250,646.98 in Q1 2024, marking a 21.7% increase[15]. - The company's cash and cash equivalents stood at RMB 1,104,801,644.13, slightly up from RMB 1,096,287,944.72, indicating a marginal increase of about 0.78%[10]. - The short-term borrowings rose to RMB 290,088,710.70 from RMB 270,309,905.42, which is an increase of approximately 7.3%[12]. - The company's retained earnings increased to RMB 973,667,050.41 from RMB 872,321,733.96, representing a growth of about 11.6%[12]. - The total equity attributable to the owners of the parent company increased by approximately 4.4% from RMB 2,271,891,202.71 to RMB 2,371,773,579.49[12]. - The company recorded a foreign exchange gain of CNY 3,875,717.81 in Q1 2025, compared to a loss of CNY 691,997.96 in Q1 2024[20].